BAJAJ BROKING

Notification close image
No new Notification messages
card image
Amanta Healthcare Ltd IPO
Apply for the Amanta Healthcare Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

7390

543434

SUPRIYA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Supriya Lifescience performance

Today’s low

Today’s high

₹ 655.30 ₹ 668.70
₹ 657.50

52 week low

52 week high

₹ 511.40 ₹ 842.00
₹ 657.50

Open Price

₹ 664.35

Prev. Close

₹ 663.60

Volume (Shares)

78682.00

Total traded value

₹ 517.33

Upper Circuit

₹ 796.30

Lower Circuit

₹ 530.90

info

Supriya Lifescience Share Price Update

As of the latest trading session, Supriya Lifescience share price is currently at ₹ 657.5, which is down by ₹ -6.09 from its previous closing. Today, the stock has fluctuated between ₹ 655.30 and ₹ 668.70. Over the past year, Supriya Lifescience has achieved a return of 24.90 %. In the last month alone, the return has been 1.03 %. Read More...

Investment Returns

Over 1 Month 1.03% Over 3 Months -7.38% Over 6 Months 12.52% Over 1 Year 24.90%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Supriya Lifescience fundamentals


  • Market cap (Cr)

    5,291.70

  • P/E Ratio (TTM)

    29.95

  • Beta

    1.84

  • Book Value / share

    123.84

  • Return on equity

    15.73%

  • EPS (TTM)

    22.13

  • Dividend yield

    0.15%

  • Net profit/quarter (Cr)

    34.79

info icon alternate text
  • Market cap (Cr)

    5,313.10

  • P/E Ratio (TTM)

    29.95

  • Beta

    1.77

  • Book Value / share

    123.84

  • Return on equity

    15.73%

  • EPS (TTM)

    22.13

  • Dividend yield

    0.15%

  • Net profit/quarter (Cr)

    34.79

info icon alternate text

Supriya Lifescience Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 145.07
Operating Expense 100.33
Net Profit 34.79
Net Profit Margin (%) 23.98
Earnings Per Share (EPS) 4.32
EBITDA 54.37
Effective Tax Rate (%) 26.61
Particulars MAR 2025 (Values in Cr)
Revenue 184.11
Operating Expense 123.03
Net Profit 50.38
Net Profit Margin (%) 27.36
Earnings Per Share (EPS) 6.29
EBITDA 70.56
Effective Tax Rate (%) 21.35
Particulars DEC 2024 (Values in Cr)
Revenue 185.65
Operating Expense 125.17
Net Profit 46.78
Net Profit Margin (%) 25.19
Earnings Per Share (EPS) 5.82
EBITDA 68.05
Effective Tax Rate (%) 25.24
Particulars SEP 2024 (Values in Cr)
Revenue 166.10
Operating Expense 106.56
Net Profit 46.15
Net Profit Margin (%) 27.78
Earnings Per Share (EPS) 5.71
EBITDA 67.23
Effective Tax Rate (%) 25.65
Particulars JUN 2024 (Values in Cr)
Revenue 160.63
Operating Expense 103.08
Net Profit 44.64
Net Profit Margin (%) 27.79
Earnings Per Share (EPS) 5.54
EBITDA 64.77
Effective Tax Rate (%) 25.31
Particulars MAR 2025 (Values in Cr)
Revenue 696.49
Operating Expense 457.82
Net Profit 187.96
Net Profit Margin (%) 26.98
Earnings Per Share (EPS) 23.35
EBITDA 270.61
Effective Tax Rate (%) 24.35
Particulars MAR 2024 (Values in Cr)
Revenue 570.37
Operating Expense 415.32
Net Profit 119.11
Net Profit Margin (%) 20.88
Earnings Per Share (EPS) 14.80
EBITDA 183.61
Effective Tax Rate (%) 28.11
Particulars MAR 2023 (Values in Cr)
Revenue 460.94
Operating Expense 346.94
Net Profit 89.86
Net Profit Margin (%) 19.49
Earnings Per Share (EPS) 11.16
EBITDA 138.39
Effective Tax Rate (%) 27.23
Particulars MAR 2022 (Values in Cr)
Revenue 530.05
Operating Expense 330.38
Net Profit 151.81
Net Profit Margin (%) 28.64
Earnings Per Share (EPS) 18.86
EBITDA 221.57
Effective Tax Rate (%) 26.75
Particulars MAR 2021 (Values in Cr)
Revenue 391.25
Operating Expense 228.91
Net Profit 123.59
Net Profit Margin (%) 31.58
Earnings Per Share (EPS) 16.89
EBITDA 178.15
Effective Tax Rate (%) 26.13
Particulars MAR 2024 (Values in Cr)
Book Value / Share 101.31
ROE % 15.73
ROCE % 22.05
Total Debt to Total Equity 0.02
EBITDA Margin 28.85
Particulars MAR 2023 (Values in Cr)
Book Value / Share 86.91
ROE % 13.67
ROCE % 18.43
Total Debt to Total Equity 0.04
EBITDA Margin 26.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 76.50
ROE % 34.34
ROCE % 41.97
Total Debt to Total Equity 0.11
EBITDA Margin 37.65
Particulars MAR 2021 (Values in Cr)
Book Value / Share 36.70
ROE % 59.18
ROCE % 55.75
Total Debt to Total Equity 0.37
EBITDA Margin 41.34
Particulars MAR 2020 (Values in Cr)
Book Value / Share 101.84
ROE % 60.41
ROCE % 46.48
Total Debt to Total Equity 0.71
EBITDA Margin 35.12
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 74.95
Total Assets 921.23
Total Liabilities 921.23
Total Equity 815.36
Share Outstanding 80482800
Price to Book Ratio 3.27
Return on Assets (%) 12.92
Return on Capital (%) 14.61
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 157.58
Total Assets 820.27
Total Liabilities 820.27
Total Equity 699.45
Share Outstanding 80482800
Price to Book Ratio 2.19
Return on Assets (%) 10.95
Return on Capital (%) 12.55
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 227.90
Total Assets 734.76
Total Liabilities 734.76
Total Equity 615.68
Share Outstanding 80482800
Price to Book Ratio 6.44
Return on Assets (%) 20.66
Return on Capital (%) 23.83
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 89.27
Total Assets 445.46
Total Liabilities 445.46
Total Equity 268.58
Share Outstanding 73183530
Price to Book Ratio 0.00
Return on Assets (%) 27.74
Return on Capital (%) 36.49
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.54
Total Assets 336.15
Total Liabilities 336.15
Total Equity 149.07
Share Outstanding 14636706
Price to Book Ratio 0.00
Return on Assets (%) 21.82
Return on Capital (%) 32.15
Particulars MAR 2024 (Values in Cr)
Net Income 165.69
Cash from Operations 150.95
Cash from Investing -173.57
Cash from Financing -22.35
Net change in Cash -82.62
Free Cash Flow 296.60
Particulars MAR 2023 (Values in Cr)
Net Income 123.48
Cash from Operations 94.28
Cash from Investing -123.65
Cash from Financing -10.27
Net change in Cash -70.32
Free Cash Flow 202.19
Particulars MAR 2022 (Values in Cr)
Net Income 207.24
Cash from Operations 109.76
Cash from Investing -59.82
Cash from Financing 149.65
Net change in Cash 138.63
Free Cash Flow 169.66
Particulars MAR 2021 (Values in Cr)
Net Income 167.30
Cash from Operations 105.88
Cash from Investing -46.80
Cash from Financing -14.51
Net change in Cash 14.57
Free Cash Flow 154.12
Particulars MAR 2020 (Values in Cr)
Net Income 96.19
Cash from Operations 143.67
Cash from Investing -25.13
Cash from Financing -29.22
Net change in Cash 62.30
Free Cash Flow 168.81
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.16 12.72 1.70 238.79 30.00 / 69.50
BLISS GVS PHARMA LTD 158.10 15.64 1.58 1667.92 105.05 / 190.65
CIPLA LTD 1587.60 23.78 4.11 128239.04 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 322.55 9.08 2.61 949.30 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2804.55 50.17 24.34 47510.77 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.16 16.93 4.92 238.79 30.00 / 69.50
AMRUTAJAN HEALTH LTD 720.55 38.21 6.37 2083.16 548.05 / 838.00
ASTRAZENECA PHARMA IND LT 8751.75 103.46 28.40 21879.38 6222.35 / 10653.05
BLISS GVS PHARMA LTD 158.10 23.63 1.57 1667.92 105.05 / 190.65

Supriya Lifescience Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
657.50 -0.91 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 661.70
  • 26 Days 670.60
  • 10 Days 664.30
  • 50 Days 678.20
  • 12 Days 665.00
  • 100 Days 681.80
  • 20 Days 668.10
  • 200 Days 658.10
662.22 PIVOT

First Support

652.68

First Resistance

673.13

Second Support

641.77

Second Resistance

682.67

Third Support

632.23

Third Resistance

693.58

RSI

46.72

ADX

25.09

MACD

-5.57

Williams % R

-43.56

Commodity Channel Index (CCI)

-9.27

Date

2025-09-01

Week

106155.00

Same Day

47000.00

Month

100879.00

1 Year

1.85

3 Year

1.17

Over 1 Month

1.03%

down

Over 1 Year

24.90%

down

Over 3 Months

-7.38%

down

Over 3 Years

23.27%

down

Over 6 Months

12.52%

down

Over 5 Years

0.00%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

Supriya Lifescience shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
20.06%
Promoter Holdings
68.29%
FII
6.77%
DII
4.86%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Satish Waman Wagh 5.4441205E7 (67.64%) Shareholding of Promoter and Promoter Group
Cohesion Mk Best Ideas Sub-trust 1710816.0 (2.13%) Public Shareholding
Aditya Birla Sun Life Insurance Company Limited 1702057.0 (2.11%) Public Shareholding
Hornbill Orchid India Fund 1520000.0 (1.89%) Public Shareholding
Smita Satish Wagh 321750.0 (0.4%) Shareholding of Promoter and Promoter Group
Shivani Satish Wagh 102375.0 (0.13%) Shareholding of Promoter and Promoter Group
Saloni Satish Wagh 102375.0 (0.13%) Shareholding of Promoter and Promoter Group
Satish Waman Wagh Partner Representing Supriyapharmaceuticals 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Arun Waman Wagh 110.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

Supriya Lifescience corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Sep 2024 0.8 Final 21 Sep 2024 Equity shares
15 Sep 2023 0.6 Final 15 Sep 2023 Equity shares
01 Sep 2022 0.6 Final 02 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Sep 2024 0.8 Final 21 Sep 2024 Equity shares
15 Sep 2023 0.6 Final 15 Sep 2023 Equity shares
01 Sep 2022 0.6 Final 02 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Supriya Lifescience Share Price

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'. The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007. Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai.

The Company commenced operations in April, 2008. It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs). The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. The company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.

The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The company's products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

The company's business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022.

In December 2021, the Company came up with an Initial Public Offer aggregating to Rs 700 crore out of which Rs 500 crore was Offer for Sale (OFS) and Rs 200 was Fresh Issue.

In 2022-23, the Company acquired a manufacturing facility with the objective of commissioning backward integration projects. The Company initiated the construction of a new warehouse and administration block, which comprises a new quality control and assurance lab. It acquired plot of land at Isambe near Patalganga for capacity expansion.

In 2023, the Company began operations at a new R&D lab in Lote Parshuram.

Parent organization Indian Private
NSE symbol SUPRIYA
Founded 2008
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Supriya Lifescience Ltd?

Answer Field

Supriya Lifescience Ltd share price is for NSE ₹ 657.50 & for BSE ₹ 656.80 as on Sep 02 2025 03:30 PM.

What is the Market Cap of Supriya Lifescience Ltd Share?

Answer Field

The market cap of Supriya Lifescience Ltd for NSE ₹ 5,291.70 & for BSE ₹ 0.00 as on Sep 02 2025 03:30 PM.

What is the 52 Week High and Low of Supriya Lifescience Ltd?

Answer Field

The 52 Week High and Low of Supriya Lifescience Ltd for NSE is ₹ 842.00 and ₹ 511.40 and for BSE is ₹ 841.70 and ₹ 511.45.

What is 1 year return for Supriya Lifescience Ltd?

Answer Field

The 1 year returns on the stock has been 24.90%.

What is the P/E Ratio of Supriya Lifescience Ltd Share?

Answer Field

As on Sep 02 2025 03:30 PM the price-to-earnings (PE) ratio for Supriya Lifescience Ltd share is 29.95.

What is the PB ratio of Supriya Lifescience Ltd Share?

Answer Field

As on Sep 02 2025 03:30 PM, the price-to-book (PB) ratio for Supriya Lifescience Ltd share is 123.84.

How to Buy Supriya Lifescience Ltd Share?

Answer Field

You can trade in Supriya Lifescience Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Supriya Lifescience Ltd Share on Bajaj Broking App?

Answer Field

To buy Supriya Lifescience Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Supriya Lifescience Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91